FDA issued a Complete Response Letter to PTC Therapeutics regarding vatiquinone for Friedreich's ataxia.

1 report, 1 independent Updated Aug 19

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA PTC Therapeutics

Keep exploring

Part of

The FDA issued a Complete Response Letter for vatiquinone, while PTC Therapeutics leveraged partnerships with Novartis and Roche, alongside benefits for AI stocks due to Trump-era tariffs. All 2 developments

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
PTC Therapeutics
pharmaceutical company

Nothing else this week.

Related events

The FDA requested additional clinical data from Unicycive Therapeutics.Jun 29

Coverage

Newest first; wire copies grouped

Aug 19PR NewswirePTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA WARREN, N.J., Aug. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Ad